Hypersensitivity to natalizumab or to any of the excipients listed in Description.
Progressive multifocal leukoencephalopathy (PML).
Patients with increased risk for opportunistic infections, including immunocompromised patients [including those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies, (see Precautions and Adverse Reactions)].
Combination with other DMTs.
Known active malignancies, except for patients with cutaneous basal cell carcinoma.